These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 26658684)
1. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. Welker MW; Luhne S; Lange CM; Vermehren J; Farnik H; Herrmann E; Welzel T; Zeuzem S; Sarrazin C J Hepatol; 2016 Apr; 64(4):790-9. PubMed ID: 26658684 [TBL] [Abstract][Full Text] [Related]
2. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432 [TBL] [Abstract][Full Text] [Related]
3. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629 [TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Modi AA; Nazario H; Trotter JF; Gautam M; Weinstein J; Mantry P; Barnes M; Habib A; McAfee J; Teachenor O; Tujague L; Gonzalez S Liver Transpl; 2016 Mar; 22(3):281-6. PubMed ID: 26335142 [TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Saxena V; Nyberg L; Pauly M; Dasgupta A; Nyberg A; Piasecki B; Winston B; Redd J; Ready J; Terrault NA Hepatology; 2015 Sep; 62(3):715-25. PubMed ID: 26033798 [TBL] [Abstract][Full Text] [Related]
6. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Younossi ZM; Stepanova M; Pol S; Bronowicki JP; Carrieri MP; Bourlière M Liver Int; 2016 Jan; 36(1):42-8. PubMed ID: 26059860 [TBL] [Abstract][Full Text] [Related]
7. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort. Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S; Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632 [TBL] [Abstract][Full Text] [Related]
9. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Welzel TM; Petersen J; Herzer K; Ferenci P; Gschwantler M; Wedemeyer H; Berg T; Spengler U; Weiland O; van der Valk M; Rockstroh J; Peck-Radosavljevic M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S Gut; 2016 Nov; 65(11):1861-1870. PubMed ID: 27605539 [TBL] [Abstract][Full Text] [Related]
10. Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. Wu SH; Chu CJ; Su CW; Lin CC; Lee SD; Wang YJ; Lee FY; Huang YH; Hou MC J Chin Med Assoc; 2019 Sep; 82(9):693-698. PubMed ID: 31356562 [TBL] [Abstract][Full Text] [Related]
11. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Omar H; El Akel W; Elbaz T; El Kassas M; Elsaeed K; El Shazly H; Said M; Yousif M; Gomaa AA; Nasr A; AbdAllah M; Korany M; Ismail SA; Shaker MK; Doss W; Esmat G; Waked I; El Shazly Y Aliment Pharmacol Ther; 2018 Feb; 47(3):421-431. PubMed ID: 29193226 [TBL] [Abstract][Full Text] [Related]
12. Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis. Essa M; Sabry A; Abdelsameea E; Tharwa ES; Salama M Eur J Gastroenterol Hepatol; 2019 Jan; 31(1):53-58. PubMed ID: 30247174 [TBL] [Abstract][Full Text] [Related]
13. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Mangia A; Arleo A; Copetti M; Miscio M; Piazzolla V; Santoro R; Squillante MM Liver Int; 2016 Jul; 36(7):971-6. PubMed ID: 26786792 [TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin. Shiffman ML; James AM; Long AG; Alexander PC Am J Gastroenterol; 2015 Aug; 110(8):1179-85. PubMed ID: 26215530 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Pellicelli AM; Pace Palitti V; Vignally P; Ceccherini-Silberstein F; Siciliano M; Giannelli V; Moretti A; Tarquini P; Scifo G; Messina V; Ascione A; Izzi A; Marignani M; D'Ambrosio C; Fondacaro L; Ettorre GM; Ialongo P; Sacco R; Perno CF; Barbarini G; Liver Int; 2017 May; 37(5):653-661. PubMed ID: 27782373 [TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. Doss W; Shiha G; Hassany M; Soliman R; Fouad R; Khairy M; Samir W; Hammad R; Kersey K; Jiang D; Doehle B; Knox SJ; Massetto B; McHutchison JG; Esmat G J Hepatol; 2015 Sep; 63(3):581-5. PubMed ID: 25937436 [TBL] [Abstract][Full Text] [Related]
17. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2. Ohya K; Akuta N; Suzuki F; Fujiyama S; Kawamura Y; Kominami Y; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H J Med Virol; 2018 May; 90(5):919-925. PubMed ID: 29315652 [TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CA; Reddy KR; Roberts SK Ann Intern Med; 2015 Dec; 163(11):809-17. PubMed ID: 26551263 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Ogawa E; Furusyo N; Nomura H; Takahashi K; Higashi N; Kawano A; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kato M; Shimoda S; Kajiwara E; Hayashi J; Antiviral Res; 2016 Dec; 136():37-44. PubMed ID: 27789224 [TBL] [Abstract][Full Text] [Related]
20. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. Tong MJ; Chang PW; Huynh TT; Rosinski AA; Tong LT J Dig Dis; 2016 Feb; 17(2):113-21. PubMed ID: 26749171 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]